Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Jan S. Sunde, et al. - Ovarian cancer is resistant to the antiproliferative effects of transforming growth factor-beta (TGF-beta); however, the mechanism of this resistance remains unclear. We used oligonucleotide arrays to profile 37 undissected, 68 microdissected advanced-stage, and 14 microdissected early-stage papillary serous cancers to identify signaling pathways involved in ovarian cancer

Related Articles

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
Journal of Oncology, 11/24/09    Relevance Score: 94%%

GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer
Breast Cancer Research and Treatment, 11/16/09    Relevance Score: 93%%

Epithelial–mesenchymal transition in ovarian cancer
Cancer Letters, 11/05/09    Relevance Score: 90%%

FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer Cells
ScienceDaily, 11/11/09    Relevance Score: 89%%

Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer
ScienceDaily, 11/10/09    Relevance Score: 89%%